STOCK TITAN

Zoetis Inc - ZTS STOCK NEWS

Welcome to our dedicated news page for Zoetis (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zoetis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zoetis's position in the market.

Rhea-AI Summary
Zoetis opens new building in Durham, N.C. for diagnostics and biodevices research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
-
Rhea-AI Summary
Zoetis, the world’s leading animal health company, is opening a new building dedicated to diagnostics and biodevices R&D. The expanded site will serve as the hub for Zoetis’ engineering and diagnostics work. The new building features over 78,000 square feet including 23,000 square feet of lab space. Zoetis employs approximately 200 people at its Durham site, more than half dedicated to R&D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Summary
Zoetis: Zoetis, the world leader in Animal Health, celebrates the opening of a new monoclonal antibodies (mAbs) expansion in Lincoln, Neb. The expansion will increase production of products for osteoarthritis pain in dogs and cats, and serve as a Veterinary Medicine R&D registration facility for future innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
Rhea-AI Summary
Zoetis Inc. (NYSE:ZTS) reported a 6% revenue growth, reaching $2.2 billion for Q2 2023, with net income increasing by 27% to $671 million. Adjusted net income was $652 million, a 15% increase. Full year 2023 revenue guidance updated to $8.500 - $8.650 billion due to foreign exchange rates impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.77%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
Zoetis Inc

NYSE:ZTS

ZTS Rankings

ZTS Stock Data

68.53B
456.86M
0.23%
95.6%
0.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Parsippany

About ZTS

Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.